Tri Locum Partners LP Acquires New Position in Insmed Incorporated (NASDAQ:INSM)

Tri Locum Partners LP bought a new position in shares of Insmed Incorporated (NASDAQ:INSM) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 316,501 shares of the biopharmaceutical company’s stock, valued at approximately $21,206,000. Insmed accounts for about 5.4% of Tri Locum Partners LP’s investment portfolio, making the stock its 7th largest holding.

Other institutional investors also recently bought and sold shares of the company. First Horizon Advisors Inc. increased its holdings in shares of Insmed by 83.4% during the 2nd quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 287 shares during the last quarter. EntryPoint Capital LLC purchased a new position in Insmed in the first quarter worth approximately $33,000. Fidelis Capital Partners LLC acquired a new stake in Insmed during the first quarter worth $34,000. CWM LLC raised its position in Insmed by 11.0% in the second quarter. CWM LLC now owns 1,570 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 155 shares during the period. Finally, Nisa Investment Advisors LLC lifted its stake in shares of Insmed by 8.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,778 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 135 shares during the last quarter.

Insider Activity

In related news, insider Martina M.D. Flammer sold 13,436 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the completion of the transaction, the insider now owns 106,134 shares in the company, valued at $7,951,559.28. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Insmed news, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $71.50, for a total transaction of $2,686,612.50. Following the sale, the insider now owns 100,100 shares of the company’s stock, valued at $7,157,150. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Martina M.D. Flammer sold 13,436 shares of the company’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the completion of the transaction, the insider now owns 106,134 shares of the company’s stock, valued at approximately $7,951,559.28. The disclosure for this sale can be found here. In the last three months, insiders have sold 78,882 shares of company stock worth $5,765,446. 4.60% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

INSM has been the subject of a number of recent analyst reports. Guggenheim raised their price objective on Insmed from $70.00 to $95.00 and gave the stock a “buy” rating in a research report on Tuesday, July 9th. Stifel Nicolaus lifted their price target on shares of Insmed from $74.00 to $88.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Wells Fargo & Company boosted their price target on shares of Insmed from $55.00 to $77.00 and gave the company an “overweight” rating in a research note on Wednesday, May 29th. Truist Financial lowered their price objective on shares of Insmed from $88.00 to $85.00 and set a “buy” rating for the company in a research report on Monday, August 12th. Finally, Evercore ISI boosted their target price on Insmed from $42.00 to $75.00 and gave the company an “outperform” rating in a research report on Friday, June 21st. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Insmed currently has an average rating of “Moderate Buy” and a consensus price target of $81.40.

Insmed Price Performance

Shares of NASDAQ INSM opened at $74.21 on Monday. The stock’s 50-day moving average is $74.68 and its two-hundred day moving average is $52.21. The company has a debt-to-equity ratio of 25.05, a current ratio of 2.71 and a quick ratio of 2.53. The company has a market cap of $11.03 billion, a price-to-earnings ratio of -14.19 and a beta of 1.11. Insmed Incorporated has a 1-year low of $21.92 and a 1-year high of $80.53.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.94) earnings per share for the quarter, missing the consensus estimate of ($1.22) by ($0.72). The company had revenue of $90.34 million for the quarter, compared to analysts’ expectations of $87.95 million. During the same quarter last year, the business posted ($1.78) earnings per share. The firm’s quarterly revenue was up 17.0% compared to the same quarter last year. Analysts forecast that Insmed Incorporated will post -5.42 EPS for the current fiscal year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.